Skip to main content
. Author manuscript; available in PMC: 2015 Jun 3.
Published in final edited form as: Cell Metab. 2014 May 15;19(6):1050–1057. doi: 10.1016/j.cmet.2014.04.005

Figure 4. Effect of β-cell-specific knockdown on responses to GLP1R agonist and DPP4i.

Figure 4

(A) Blood glucose during IPGTT in tamoxifen or vehicle-treated MIPcreER;Glp1rf/f (Tam, blue or Veh, red) mice given liraglutide (200 ug/kg) or saline 4 hours prior to glucose injection. (B) AUC from GTT in A. (C) OGTT in tamoxifen and vehicle-treated MIPcreER;Glp1rf/f mice given IP vildagliptin (150 ug) or saline (100 ul) 15 minutes before the glucose challenge. (D) AUC from GTT in C. (E) Blood glucose during IPGTT in tamoxifen- and vehicle-treated MIPcreER;Glp1rf/f mice given IP saline or vildagliptin (150 ug) 30 minutes prior to glucose injection. (F) AUC from GTT in E. Experiments used 8–16 mice per group, with * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. (See Figure S4)